Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel in Heavily Pretreated Metastatic Breast Cancer
NCT02041351Phase 2Completed
- Sponsor
- Centro Universitario contra el Cáncer
- Start
- Nov 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel in breast cancer, sponsored by Centro Universitario contra el Cáncer. Primary endpoint: Disease-Free Interval at 4 months. Started Nov 2013; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02041351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041351.